Es gab 50 kürzliche Insider-Transaktionen für Nurix Therapeutics, Inc. (NRIX), darunter 21 Käufe und 27 Verkäufe. Die gesamten Insider-Käufe beliefen sich auf $20.2M und die gesamten Insider-Verkäufe auf $1.06M.
Bedeutende Insider mit kürzlicher Aktivität umfassen Ring Christine, Sands Arthur T, Hansen Gwenn. Insider-Transaktionen können Einblicke geben, wie die Unternehmensführung die Bewertung und Zukunftsaussichten der Aktie einschätzt.
Insider-Transaktionen — NRIX
| Datum |
Name |
Funktion |
Transaktionsart |
Aktien |
Ø Preis |
Wert |
Gehaltene Aktien |
| 2026-04-02 |
Ring Christine |
Chief Legal Officer |
Informierter Verkauf |
8,148 |
$15.24 |
$124.15K |
26,453 |
| 2026-03-02 |
Ring Christine |
Chief Legal Officer |
Informierter Verkauf |
8,148 |
$15.44 |
$125.79K |
34,601 |
| 2026-02-10 |
Sands Arthur T |
President, CEO |
RSU-Zuteilung |
562,500 |
$16.45 |
$9.25M |
562,500 |
| 2026-02-10 |
Hansen Gwenn |
Chief Scientific Officer |
RSU-Zuteilung |
42,875 |
- |
- |
42,875 |
| 2026-02-10 |
Ring Christine |
Chief Legal Officer |
RSU-Zuteilung |
42,875 |
- |
- |
42,875 |
| 2026-02-10 |
Van Houte Hans |
Chief Financial Officer |
RSU-Zuteilung |
42,875 |
- |
- |
42,875 |
| 2026-02-09 |
Ring Christine |
Chief Legal Officer |
Informierter Verkauf |
14,261 |
$16.66 |
$237.62K |
42,749 |
| 2026-02-03 |
Hansen Gwenn |
Chief Scientific Officer |
Optionsausübung (Verkauf) |
31,333 |
$0.84 |
$26.32K |
- |
| 2026-01-30 |
Hansen Gwenn |
Chief Scientific Officer |
Optionsausübung (Verkauf) |
3,207 |
- |
- |
- |
| 2026-01-30 |
Ring Christine |
Chief Legal Officer |
Optionsausübung (Verkauf) |
1,925 |
- |
- |
- |
| 2026-01-30 |
Van Houte Hans |
Chief Financial Officer |
Optionsausübung (Verkauf) |
2,887 |
- |
- |
- |
| 2026-01-20 |
Ring Christine |
Chief Legal Officer |
Optionsausübung (Verkauf) |
3,760 |
$1.86 |
$6.99K |
8,643 |
| 2025-12-18 |
Ring Christine |
Chief Legal Officer |
Optionsausübung (Verkauf) |
3,760 |
$1.86 |
$6.99K |
12,403 |
| 2025-11-24 |
Ring Christine |
Chief Legal Officer |
Optionsausübung (Verkauf) |
37,600 |
$1.86 |
$69.94K |
16,163 |
| 2025-11-06 |
Dansey Roger D |
Director |
Unbekannt |
- |
- |
- |
- |
| 2025-11-06 |
Dansey Roger D |
Director |
RSU-Zuteilung |
50,000 |
$12.52 |
$626K |
50,000 |
| 2025-11-03 |
Van Houte Hans |
Chief Financial Officer |
Informierter Verkauf |
6,284 |
$12.56 |
$78.93K |
37,592 |
| 2025-10-30 |
Hansen Gwenn |
Chief Scientific Officer |
Optionsausübung (Verkauf) |
3,207 |
- |
- |
3,207 |
| 2025-10-30 |
Ring Christine |
Chief Legal Officer |
Optionsausübung (Verkauf) |
1,924 |
- |
- |
1,925 |
| 2025-10-30 |
Van Houte Hans |
Chief Financial Officer |
Optionsausübung (Verkauf) |
2,886 |
- |
- |
2,887 |
| 2025-10-14 |
Hansen Gwenn |
Chief Scientific Officer |
RSU-Zuteilung |
20,000 |
- |
- |
20,000 |
| 2025-09-17 |
Gregory Julia P |
Director |
Optionsausübung |
10,750 |
$1.86 |
$20K |
10,750 |
| 2025-08-01 |
Van Houte Hans |
Chief Financial Officer |
Informierter Verkauf |
5,402 |
$11.03 |
$59.6K |
35,512 |
| 2025-07-30 |
Ring Christine |
Chief Legal Officer |
Optionsausübung |
1,924 |
- |
- |
39,242 |
| 2025-07-30 |
Van Houte Hans |
Chief Financial Officer |
Optionsausübung (Verkauf) |
2,886 |
- |
- |
5,773 |
| 2025-05-19 |
Gregory Julia P |
Director |
RSU-Zuteilung |
25,000 |
$9.51 |
$237.75K |
25,000 |
| 2025-05-19 |
Reinsdorf Judith A |
Director |
RSU-Zuteilung |
25,000 |
$9.51 |
$237.75K |
25,000 |
| 2025-05-19 |
Silva Paul M |
Director |
RSU-Zuteilung |
25,000 |
$9.51 |
$237.75K |
25,000 |
| 2025-05-19 |
Kunkel Lori Anne |
Director |
RSU-Zuteilung |
25,000 |
$9.51 |
$237.75K |
25,000 |
| 2025-05-19 |
Baynes Roy D. |
Director |
RSU-Zuteilung |
25,000 |
$9.51 |
$237.75K |
25,000 |
| 2025-05-19 |
Kapur Anil |
Director |
RSU-Zuteilung |
25,000 |
$9.51 |
$237.75K |
25,000 |
| 2025-05-19 |
Lacey David L. |
Director |
RSU-Zuteilung |
25,000 |
$9.51 |
$237.75K |
25,000 |
| 2025-05-19 |
Saltzman Edward C |
Director |
RSU-Zuteilung |
25,000 |
$9.51 |
$237.75K |
25,000 |
| 2025-05-02 |
Van Houte Hans |
Chief Financial Officer |
Informierter Verkauf |
6,198 |
$11.33 |
$70.24K |
33,724 |
| 2025-04-30 |
Hansen Gwenn |
Chief Scientific Officer |
Optionsausübung (Verkauf) |
2,000 |
- |
- |
8,000 |
| 2025-04-30 |
Ring Christine |
Chief Legal Officer |
Optionsausübung (Verkauf) |
1,924 |
- |
- |
5,773 |
| 2025-04-30 |
Van Houte Hans |
Chief Financial Officer |
Optionsausübung (Verkauf) |
2,000 |
- |
- |
8,000 |
| 2025-03-11 |
Baynes Roy D. |
Director |
Unbekannt |
10,000 |
$9.25 |
$92.5K |
- |
| 2025-03-11 |
Baynes Roy D. |
Director |
RSU-Zuteilung |
50,000 |
$13.90 |
$695K |
50,000 |
| 2025-03-03 |
Van Houte Hans |
Chief Financial Officer |
Informierter Verkauf |
700 |
$15.13 |
$10.59K |
33,724 |
| 2025-02-11 |
Sands Arthur T |
President, CEO |
RSU-Zuteilung |
450,000 |
$17.12 |
$7.7M |
450,000 |
| 2025-02-11 |
Hansen Gwenn |
Chief Scientific Officer |
RSU-Zuteilung |
34,300 |
- |
- |
34,300 |
| 2025-02-11 |
Ring Christine |
Chief Legal Officer |
RSU-Zuteilung |
34,300 |
- |
- |
34,300 |
| 2025-02-11 |
Van Houte Hans |
Chief Financial Officer |
RSU-Zuteilung |
34,300 |
- |
- |
34,300 |
| 2025-01-31 |
Ring Christine |
Chief Legal Officer |
Optionsausübung (Verkauf) |
5,537 |
$1.86 |
$10.3K |
- |
| 2025-01-30 |
Hansen Gwenn |
Chief Scientific Officer |
Optionsausübung (Verkauf) |
2,000 |
- |
- |
10,000 |
| 2025-01-30 |
Ring Christine |
Chief Legal Officer |
Optionsausübung (Verkauf) |
1,924 |
- |
- |
7,697 |
| 2025-01-30 |
Van Houte Hans |
Chief Financial Officer |
Optionsausübung (Verkauf) |
2,000 |
- |
- |
10,000 |
| 2025-01-02 |
Ring Christine |
Chief Legal Officer |
Informierter Verkauf |
5,760 |
$19.50 |
$112.29K |
28,084 |
| 2024-12-02 |
Ring Christine |
Chief Legal Officer |
Informierter Verkauf |
5,760 |
$21.73 |
$125.16K |
28,084 |
■ Informativ — Transaktion am offenen Markt (bedeutendste)
■ Nicht-informativ (Kauf) — Vergütung, Optionsausübung, Wandlung
■ Nicht-informativ (Verkauf) — Quellensteuer, Verkauf bei Vesting
■ Neutral — Schenkung, Treuhand, Verfall
